Shionogi & Co logo

4507 - Shionogi & Co News Story

¥6043 -33.0  -0.5%

Last Trade - 07/08/20

Sector
Healthcare
Size
Large Cap
Market Cap £13.23bn
Enterprise Value £10.73bn
Revenue £2.25bn
Position in Universe 67th / 3862

CORRECTED-UPDATE 1-Japan's Shionogi partners with universities to develop visual coronavirus test

Mon 22nd June, 2020 2:49am
(Corrects name of method in second paragraph to SATIC, not
STATIC)
    June 22 (Reuters) - Shionogi & Co Ltd  4507.T  said it is
partnering with Japanese universities to develop a saliva test
for coronavirus that can yield visual results in 25 minutes. 
    The method, known as SATIC, involves heating a sample of
saliva and adding it to a reagent that changes color to indicate
the presence of viruses, according to a news release by the
company on Monday. Patients can take their own samples, and
readings can be made without detector equipment.
    The accuracy of the tests are equivalent to those by
polymerise chain reaction (PCR) tests, the company said.
Shionogi is licensing the technology from Nihon University,
Gunma University, and Tokyo Medical University. 
    Japan approved saliva-based tests for the coronavirus
earlier this month, offering a safer, simpler way to diagnose
infection than nasal swabs.  urn:newsml:reuters.com:*:nL4N2DF0J9  urn:newsml:reuters.com:*:nL4N2DU0ND

 (Editing by Kim Coghill)
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.